Pcn171 - A Cost-Utility Analysis of Fulvestrant Versus Anastrozole as First-Line Therapy for Oestrogen Receptor-Positive Locally Advanced and Metastatic Breast Cancer

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.254
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cost-Effectiveness of Palbociclib Plus Letrozole Versus Letrozole Alone as a First-Line Treatment in Women With Oestrogen Receptor-Positive, HER2-negative, Advanced Breast Cancer. Revised Results for the Swiss Health Care Setting

Breast Cancer Research and Treatment
Cancer ResearchOncology
2017English

Cost Effectiveness of Fulvestrant 500 Mg in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer in the UK

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

A Comparison of Fulvestrant Plus a Targeted Agent With Fulvestrant Alone in Hormone Receptor-Positive Advanced Breast Cancer That Progressed on Prior Endocrine Therapy: A Meta-Analysis

OncoTargets and Therapy
OncologyPharmacology
2018English

Trial-Based Cost-Utility Analysis of Icotinib Versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China

PLoS ONE
Multidisciplinary
2016English

A Randomized Trial of Combination Anastrozole Plus Gefitinib and of Combination Fulvestrant Plus Gefitinib in the Treatment of Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2012English

Cost-Effectiveness and Cost-Utility Analysis of Sunitinib Versus Sorafenib and Bevacizumab + Interferon-Alfa as First-Line Treatment for Metastatic Renal Cell Carcinoma in Ecuador

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus as First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2013English

Exemestane as Third and Fourth Line Hormonal Therapy for Metastatic Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2000English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy